GlassScriptPhysician profile
Sandra L Spedale
NPI 1104812544
$3,025.55
in general payments reported to CMS, 2019-2025
29 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2021: $299 · 2022: $286 · 2023: $343 · 2024: $170 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $858.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $260.58 | 2019-2023 | |
| Novo Nordisk INC | $240.65 | 2019-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $225.96 | 2019 | |
| Abbvie INC. | $223.66 | 2021-2025 | Viberzi, Linzess, Vraylar |
| Pfizer INC. | $142.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $127.43 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.02 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $100.61 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $86.29 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $71.50 | 2019 | |
| Amarin Pharma, INC. | $47.55 | 2019 | |
| Astellas Pharma US INC | $43.09 | 2019 | |
| Abbott Laboratories | $39.53 | 2019-2023 | Freestyle Libre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $39.27 | 2019 | |
| Allergan, INC. | $29.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.32 | 2019 | |
| Dexcom, INC. | $23.99 | 2025 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $21.19 | 2019 | |
| Cipher Pharmaceuticals US LLC | $21.05 | 2025 | Natroba, Spinosad |
| Ironwood Pharmaceuticals, INC | $18.69 | 2021 | |
| Sanofi Pasteur INC. | $17.54 | 2019 | |
| Qiagen, LLC | $16.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.43 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $15.36 | 2023 | Inspire |
| Theratechnologies INC. | $14.59 | 2022 | |
| Medtronic USA, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Spedale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.